Report cover image

Sepsis Diagnostics Market Report and Forecast 2025-2034

Published Jul 27, 2025
Length 350 Pages
SKU # EMAR20319639

Description

The global sepsis diagnostics market size was valued at USD 725.60 Million in 2024, driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. The market is expected to grow at a CAGR of 9.10% during the forecast period of 2025-2034, with the values likely to reach USD 1733.58 Million by 2034.

Sepsis Diagnostics: Introduction

Sepsis is a condition characterized by the body’s abnormal response to an infection. Common symptoms may include sweating, shivering, change in mental status, and shallow breathing, among others. The condition can be diagnosed via blood tests, which help in detecting evidence of infection, abnormal liver or kidney function, electrolyte imbalances or blood clotting issues. The imaging tests may include x-ray, ultrasound, CT scans, and MRIs.

Global Sepsis Diagnostics Market Analysis

Sepsis is one of the leading causes of deaths in the world. As per studies, early diagnosis can significantly help lower the fatalities associated with the condition. Therefore, there has been rising demand for sepsis diagnostics.

The sepsis diagnostics market growth is driven by the rising merger and acquisitions amongst companies to offer early diagnosis of the condition. In September 2023, Acutelines, a data-biobank and Inflammatix, a molecular diagnostics company announced their strategic partnership to develop a smart tool that helps in the recognition of sepsis while supporting clinical decisions in the early stages of the disease. This can mark as a crucial step since early recognition can be quite difficult in this condition.

With deeper understanding of human physiology and improved biotechnology techniques, the market for sepsis diagnostics has been experiencing major advancements. For instance, In November 2023, Abionic, along with their biomedical technology partner Lascco, entered a licensing agreement with Fapon, to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis.

SeptiCyte® RAPID by Immunexpress is another molecular test for sepsis diagnosis that employs the RT-PCR test to quantify the level of host response genes. It is intended for in-vitro diagnostic use and runs on the Biocartis Idylla™ Platform. Emerging technologies like these will certainly benefit the sepsis diagnostics market value in the forecast period.

Global Sepsis Diagnostics Market Segmentation

“Sepsis Diagnostics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type
  • Instruments
  • Blood Culture Media
  • Assay Kits and Reagents
  • Software
Market Breakup by Technology
  • Microbiology
  • Molecular Diagnostics
  
  • Polymerase Chain Reaction (PCR)

  •   
  • DNA Microarrays

  •   
  • Syndromic Panel Testing

  •   
  • Others
    • Immunoassays
    • Flow Cytometry
    • Others
    Market Breakup by Pathogen
    • Bacterial Sepsis
      
  • Gram-positive Bacteria

  •   
  • Gram-negative Bacteria
    • Fungal Sepsis
    • Viral Sepsis
    • Others
    Market Breakup by Type
    • Laboratory Testing
    • POC Testing
    Market Breakup by Methods
    • Automated Diagnostics
    • Conventional Diagnostics
    Market Breakup by End User
    • Hospitals and Clinics
    • Pathology and Reference Laboratories
    • Research Institutes
    • Others
    Market Breakup by Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
    Global Sepsis Diagnostics Market Overview

    The United States holds a substantial part of the sepsis diagnostics market share owing to a robust healthcare infrastructure. Increasing effort of the government and private institutions to offer awareness about the condition also plays a vital role for market growth. In July 2023, the Society of Critical Care Medicine (SCCM) received a grant from the Council of Medical Specialty Societies to enhance diagnostic excellence. The diagnostic program by SCCM focuses on providing knowledge and technology for precise diagnosis with the help of podcasts, toolkits, and webcasts.

    The Asia Pacific region is projected to witness further growth with the increasing sepsis diagnostics market demand in the region. With increasing mergers and collaborations, the government has also been working on improving the medical infrastructure with a vision to integrate all digital and artificial intelligence-based tools into the system. A large population base spanning from the old as well as young generations is another essential factor for increased market demand.

    Global Sepsis Diagnostics Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • BioMérieux SA
    • Becton, Dickinson and Company
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche AG
    • Danaher Corporation
    • Luminex Corp.
    • Bruker Corp.
    • Cepheid
    • Bruker Corporation
    • Immunexpress, Inc.
    • Nanosphere, Inc.
    • Seegene Inc.
    • Response Biomedical Corp.
    • Quidel Corporation
    • Koninklijke Philips N.V.
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Global Sepsis Diagnostics Market Overview
    3.1 Global Sepsis Diagnostics Market Historical Value (2018-2024)
    3.2 Global Sepsis Diagnostics Market Forecast Value (2025-2034)
    4 Global Sepsis Diagnostics Market Landscape
    4.1 Global Sepsis Diagnostics Developers Landscape
    4.1.1 Analysis by Year of Establishment
    4.1.2 Analysis by Company Size
    4.1.3 Analysis by Region
    4.2 Global Sepsis Diagnostics Product Landscape
    4.2.1 Analysis by Type
    4.2.2 Analysis by Technology
    4.2.3 Analysis by Pathogen
    5 Global Sepsis Diagnostics Market Dynamics
    5.1 Market Drivers and Constraints
    5.2 SWOT Analysis
    5.3 Porter’s Five Forces Model
    5.4 Key Demand Indicators
    5.5 Key Price Indicators
    5.6 Industry Events, Initiatives, and Trends
    5.7 Value Chain Analysis
    6 Global Sepsis Diagnostics Market Segmentation
    6.1 Global Sepsis Diagnostics Market by Product Type
    6.1.1 Market Overview
    6.1.2 Instruments
    6.1.3 Blood Culture Media
    6.1.4 Assay Kits and Reagents
    6.1.5 Software
    6.2 Global Sepsis Diagnostics Market by Technology
    6.2.1 Market Overview
    6.2.2 Microbiology
    6.2.3 Molecular Diagnostics
    6.2.3.1 Polymerase Chain Reaction (PCR)
    6.2.3.2 DNA Microarrays
    6.2.3.3 Syndromic Panel Testing
    6.2.3.4 Others
    6.2.4 Immunoassays
    6.2.5 Flow Cytometry
    6.2.6 Others
    6.3 Global Sepsis Diagnostics Market by Pathogen
    6.3.1 Market Overview
    6.3.2 Bacterial Sepsis
    6.3.2.1 Gram-positive Bacteria
    6.3.2.2 Gram-negative Bacteria
    6.3.3 Fungal Sepsis
    6.3.4 Viral Sepsis
    6.3.5 Others
    6.4 Global Sepsis Diagnostics Market by Type
    6.4.1 Market Overview
    6.4.2 Laboratory Testing
    6.4.3 POC Testing
    6.5 Global Sepsis Diagnostics Market by Methods
    6.5.1 Market Overview
    6.5.2 Automated Diagnostics
    6.5.3 Conventional Diagnostics
    6.6 Global Sepsis Diagnostics Market by End User
    6.6.1 Market Overview
    6.6.2 Hospitals and Clinics
    6.6.3 Pathology and Reference Laboratories
    6.6.4 Research Institutes
    6.6.5 Others
    6.7 Global Sepsis Diagnostics Market by Region
    6.7.1 Market Overview
    6.7.2 North America
    6.7.3 Europe
    6.7.4 Asia Pacific
    6.7.5 Latin America
    6.7.6 Middle East and Africa
    7 North America Sepsis Diagnostics Market
    7.1 Market Share by Country
    7.2 United States of America
    7.3 Canada
    8 Europe Sepsis Diagnostics Market
    8.1 Market Share by Country
    8.2 United Kingdom
    8.3 Germany
    8.4 France
    8.5 Italy
    8.6 Others
    9 Asia Pacific Sepsis Diagnostics Market
    9.1 Market Share by Country
    9.2 China
    9.3 Japan
    9.4 India
    9.5 ASEAN
    9.6 Australia
    9.7 Others
    10 Latin America Sepsis Diagnostics Market
    10.1 Market Share by Country
    10.2 Brazil
    10.3 Argentina
    10.4 Mexico
    10.5 Others
    11 Middle East and Africa Sepsis Diagnostics Market
    11.1 Market Share by Country
    11.2 Saudi Arabia
    11.3 United Arab Emirates
    11.4 Nigeria
    11.5 South Africa
    11.6 Others
    12 Patent Analysis
    12.1 Analysis by Type of Patent
    12.2 Analysis by Publication year
    12.3 Analysis by Issuing Authority
    12.4 Analysis by Patent Age
    12.5 Analysis by CPC Analysis
    12.6 Analysis by Patent Valuation
    12.7 Analysis by Key Players
    13 Grants Analysis
    13.1 Analysis by year
    13.2 Analysis by Amount Awarded
    13.3 Analysis by Issuing Authority
    13.4 Analysis by Grant Application
    13.5 Analysis by Funding Institute
    13.6 Analysis by NIH Departments
    13.7 Analysis by Recipient Organization
    14 Funding Analysis
    14.1 Analysis by Funding Instances
    14.2 Analysis by Type of Funding
    14.3 Analysis by Funding Amount
    14.4 Analysis by Leading Players
    14.5 Analysis by Leading Investors
    14.6 Analysis by Geography
    15 Partnership and Collaborations Analysis
    15.1 Analysis by Partnership Instances
    15.2 Analysis by Type of Partnership
    15.3 Analysis by Leading Players
    15.4 Analysis by Geography
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 INDIA CDSCO
    16.1.4 JAPAN PMDA
    16.1.5 Others
    17 Supplier Landscape
    17.1 BioMérieux SA
    17.1.1 Financial Analysis
    17.1.2 Product Portfolio
    17.1.3 Demographic Reach and Achievements
    17.1.4 Mergers and Acquisition
    17.1.5 Certifications
    17.2 Becton, Dickinson and Company
    17.2.1 Financial Analysis
    17.2.2 Product Portfolio
    17.2.3 Demographic Reach and Achievements
    17.2.4 Mergers and Acquisition
    17.2.5 Certifications
    17.3 Thermo Fisher Scientific, Inc.
    17.3.1 Financial Analysis
    17.3.2 Product Portfolio
    17.3.3 Demographic Reach and Achievements
    17.3.4 Mergers and Acquisition
    17.3.5 Certifications
    17.4 F. Hoffmann-La Roche AG
    17.4.1 Financial Analysis
    17.4.2 Product Portfolio
    17.4.3 Demographic Reach and Achievements
    17.4.4 Mergers and Acquisition
    17.4.5 Certifications
    17.5 Danaher Corporation
    17.5.1 Financial Analysis
    17.5.2 Product Portfolio
    17.5.3 Demographic Reach and Achievements
    17.5.4 Mergers and Acquisition
    17.5.5 Certifications
    17.6 Luminex Corp.
    17.6.1 Financial Analysis
    17.6.2 Product Portfolio
    17.6.3 Demographic Reach and Achievements
    17.6.4 Mergers and Acquisition
    17.6.5 Certifications
    17.7 Bruker Corp.
    17.7.1 Financial Analysis
    17.7.2 Product Portfolio
    17.7.3 Demographic Reach and Achievements
    17.7.4 Mergers and Acquisition
    17.7.5 Certifications
    17.8 Cepheid
    17.8.1 Financial Analysis
    17.8.2 Product Portfolio
    17.8.3 Demographic Reach and Achievements
    17.8.4 Mergers and Acquisition
    17.8.5 Certifications
    17.9 Bruker Corporation
    17.9.1 Financial Analysis
    17.9.2 Product Portfolio
    17.9.3 Demographic Reach and Achievements
    17.9.4 Mergers and Acquisition
    17.9.5 Certifications
    17.10 Immunexpress, Inc.
    17.10.1 Financial Analysis
    17.10.2 Product Portfolio
    17.10.3 Demographic Reach and Achievements
    17.10.4 Mergers and Acquisition
    17.10.5 Certifications
    17.11 Nanosphere, Inc.
    17.11.1 Financial Analysis
    17.11.2 Product Portfolio
    17.11.3 Demographic Reach and Achievements
    17.11.4 Mergers and Acquisition
    17.11.5 Certifications
    17.12 Seegene Inc.
    17.12.1 Financial Analysis
    17.12.2 Product Portfolio
    17.12.3 Demographic Reach and Achievements
    17.12.4 Mergers and Acquisition
    17.12.5 Certifications
    17.13 Response Biomedical Corp.
    17.13.1 Financial Analysis
    17.13.2 Product Portfolio
    17.13.3 Demographic Reach and Achievements
    17.13.4 Mergers and Acquisition
    17.13.5 Certifications
    17.14 Quidel Corporation
    17.14.1 Financial Analysis
    17.14.2 Product Portfolio
    17.14.3 Demographic Reach and Achievements
    17.14.4 Mergers and Acquisition
    17.14.5 Certifications
    17.15 Koninklijke Philips N.V.
    17.15.1 Financial Analysis
    17.15.2 Product Portfolio
    17.15.3 Demographic Reach and Achievements
    17.15.4 Mergers and Acquisition
    17.15.5 Certifications
    18 Global Sepsis Diagnostics Market - Distribution Model (Additional Insight)
    18.1 Overview
    18.2 Potential Distributors
    18.3 Key Parameters for Distribution Partner Assessment
    19 Key Opinion Leaders (KOL) Insights (Additional Insight)
    20 Company Competitiveness Analysis (Additional Insight)
    20.1 Very Small Companies
    20.2 Small Companies
    20.3 Mid-Sized Companies
    20.4 Large Companies
    20.5 Very Large Companies
    21 Payment Methods (Additional Insight)
    21.1 Government Funded
    21.2 Private Insurance
    21.3 Out-of-Pocket
    How Do Licenses Work?
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.